دورية أكاديمية
Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.
| العنوان: | Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. |
|---|---|
| المؤلفون: | Pavord ID; Nuffield Department of Medicine and Oxford Respiratory NIHR BRC, University of Oxford, Oxford, United Kingdom., Menzies-Gow A; Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom., Buhl R; Pulmonary Department, Mainz University Hospital, Mainz, Germany., Chanez P; Aix-Marseille Université, INSERM CV2N, APHM CIC NORD, Marseille, France., Dransfield M; Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Ala., Lugogo N; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich., Keene ON; Biostatistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom., Bradford ES; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC., Yancey SW; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC. Electronic address: steve.w.yancey@gsk.com. |
| المصدر: | The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2021 Mar; Vol. 9 (3), pp. 1121-1132.e7. Date of Electronic Publication: 2020 Sep 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Elsevier Inc., [2013]- |
| مواضيع طبية MeSH: | Anti-Asthmatic Agents*/therapeutic use , Asthma*/drug therapy, Antibodies, Monoclonal, Humanized/therapeutic use ; Eosinophils ; Humans ; Precision Medicine |
| مستخلص: | The development of mepolizumab, an anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma, is an example of a clinical development program that evolved over time based on sound, basic scientific principles. Initial clinical data on the effects of mepolizumab on lung function in a general asthmatic population were disappointing. However, it became clear that mepolizumab may be more effective against other clinical endpoints, particularly asthma exacerbations, in patients with more severe disease. Furthermore, a developing understanding of asthma disease pathobiology led to the identification of an appropriate target population and predictive biomarker for mepolizumab treatment: patients with severe eosinophilic asthma and blood eosinophil count. Mepolizumab use provides clinically meaningful benefits in this target population, fulfilling an unmet need. This Clinical Commentary Review describes the clinical development of mepolizumab and details of how this program informed the development of other biologic therapies in patients with severe asthma. This account highlights how a personalized approach toward treatment of patients with severe eosinophilic asthma, supported by a large body of scientific evidence, ultimately led to new and effective treatments and improved patient outcomes. (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Anti-IL-5; Biologic therapy; Mepolizumab; Severe eosinophilic asthma |
| المشرفين على المادة: | 0 (Anti-Asthmatic Agents) 0 (Antibodies, Monoclonal, Humanized) 90Z2UF0E52 (mepolizumab) |
| تواريخ الأحداث: | Date Created: 20200905 Date Completed: 20210524 Latest Revision: 20210524 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.jaip.2020.08.039 |
| PMID: | 32889223 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2213-2201 |
|---|---|
| DOI: | 10.1016/j.jaip.2020.08.039 |